DXB 8.89% 49.0¢ dimerix limited

Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA, page-5

  1. 1,839 Posts.
    lightbulb Created with Sketch. 280
    Yes very positive
    Would DXB be progressing like this :

    The Phase 3 protocol proposal is also under review by the FDA and MHRA (UK regulatory agency), and
    a virtual meeting between the FDA and Dimerix has been scheduled to confirm that specific study
    design endpoints also meet the criteria required to support accelerated approval for FSGS in the US.
    Once confirmed, Dimerix can begin initiating clinical sites globally and subsequent recruitment of
    patients, which is expected early Q3-2021.

    without funding lined up??
    or are they banking on one of the two covid study outcomes providing SP support to fund?
    I hope we get news soon regarding funding and my hope is that Big Pharma are in discussions. Cheers.

 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
49.0¢
Change
0.040(8.89%)
Mkt cap ! $269.6M
Open High Low Value Volume
46.0¢ 50.5¢ 46.0¢ $2.255M 4.621M

Buyers (Bids)

No. Vol. Price($)
1 100000 49.0¢
 

Sellers (Offers)

Price($) Vol. No.
49.5¢ 21052 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.